机构名称：
¥ 1.0
In a continued effort to be at the forefront of science, Part the Cloud has launched a new fundraising initiative — the Gene Targeting Challenge — to supercharge the development of therapies tailored to the genetic underpinnings of Alzheimer's disease. This challenge, which will support new and ongoing early-stage clinical trials using gene targeting, is what Part the Cloud does best: investing in big, bold ideas that will move the needle in our quest to end Alzheimer's and all other dementia. In this impact report, you'll read more about the new Gene Targeting Challenge, as well as Part the Cloud's current global impact on the Alzheimer's drug pipeline broadly.
Part the Cloud 2023 Impact Report
主要关键词
相关文件推荐
